Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
G J CreemersW ten Bokkel Huinink

Abstract

Topotecan is a topoisomerase I inhibitor with preclinical activity against various tumor types. We conducted a large multicenter phase II study with topotecan in ovarian cancer in patients who had failed to respond to one prior cisplatin-based chemotherapeutic regimen. Topotecan 1.5 mg/m2/d was administered intravenously by 30-minute infusion for 5 days repeated every 3 weeks. As the cisplatin-free interval relates to response in subsequent treatment, patients were stratified in subgroups, ie, cisplatin-refractory, cisplatin-resistant, and cisplatin-sensitive. One-hundred eleven patients entered the study. Nineteen patients were considered to be ineligible; 92 patients were assessable for response. A total of 552 courses were given (median, four per patient; range, one to 17). The major toxicities were leukocytopenia and neutropenia, which were grade 3 to 4 in 54.2% and 69.1% of courses, respectively, but with only 4.3% of these being grade 4 neutropenia plus fever or infectious complications. Prophylactic granulocyte colony-stimulating factor (G-CSF) was given in 20.5% of courses to maintain dose-intensity. Other relatively frequent side effects were alopecia (82%), nausea (36.4%), and vomiting (17.5%). The overall response ra...Continue Reading

Citations

Mar 10, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S A Cannistra
Feb 6, 1999·International Journal of Cancer. Journal International Du Cancer·D M Katschinski, H I Robins
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H HochsterJ Speyer
Jun 17, 2000·American Journal of Clinical Oncology·C W RyanM J Ratain
Dec 21, 2000·Current Oncology Reports·A A Garcia
Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M E RoyceR Pazdur
Aug 8, 2001·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·P F ConteC Cianci
Jul 4, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A BowmanJ F Smyth
Sep 27, 2002·The Oncologist·Robert Morris, Adnan Munkarah
Aug 2, 2002·American Journal of Clinical Oncology·Nasser H HannaAlan B Sandler
Mar 27, 2003·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·S GhamandeK Odunsi
Dec 3, 2004·Cancer Investigation·Jonathan A Ledermann, Sarah Wheeler
Jan 18, 2006·Pediatric Blood & Cancer·Andrea HunoldHerbert Jürgens
Jul 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven Joffe, Franklin G Miller
Nov 27, 2008·Journal of Cancer Research and Clinical Oncology·Lubomir BodnarCezary Szczylik
Feb 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul J Hoskins
Jul 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jalid SehouliWerner Lichtenegger
May 2, 2009·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Marco CalcagnoPierluigi Benedetti Panici
Jan 25, 2018·The Biochemical Journal·Justine L DelgadoHiroshi Hiasa
Jan 7, 1999·The Annals of Pharmacotherapy·R J Cersosimo
Mar 10, 2001·American Journal of Clinical Oncology·J GiblinW P McGuire
Jun 12, 2002·Current Treatment Options in Oncology·Martee L Hensley
Sep 7, 2000·Current Opinion in Oncology·G Deppe, P Baumann
Mar 4, 1998·Current Opinion in Obstetrics & Gynecology·I Benjamin, S C Rubin
Nov 8, 2001·Leukemia & Lymphoma·K SeiterT Ahmed
Oct 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D L Clarke-PearsonS Z Fields
Nov 25, 2003·Cancer Investigation·David M BorutaLinda Van Le
Oct 27, 2004·Expert Opinion on Pharmacotherapy·Tanya Ahmad, Martin Gore
Sep 22, 2005·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·S K MitchellL S Downs
Jul 15, 2005·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·B Piura, A Rabinovich
Apr 22, 2008·The Cochrane Database of Systematic Reviews·L H PengT X Wu
Jan 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard HochsterFranco M Muggia
May 26, 2006·Expert Opinion on Pharmacotherapy·D PectasidesT Economopoulos
Oct 17, 2006·Current Oncology Reports·Thomas J Herzog
Sep 3, 2009·Annals of the New York Academy of Sciences·Hee Seung KimYong Sang Song
May 23, 2012·Investigational New Drugs·Nilesh A PatankarMarcel B Bally

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Eric H KrautS E Salmon
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
T J LynchE Frei
Annals of Oncology : Official Journal of the European Society for Medical Oncology
G J CreemersJ Verweij
© 2021 Meta ULC. All rights reserved